Earnings per share for the last twelve months: Puma Biotechnology Inc (PBYI)

PBYI (Puma Biotechnology Inc) - company brandmark

Puma Biotechnology relies on outsourcing for production and testing to maintain workforce flexibility. The 12-month rolling revenue per employee metric on the GURU.Markets chart confirms this trajectory, where 0.46 shows the current value of the metric. However, dependence on a single drug creates margin risks, and a minimal environmental footprint is achieved solely through digital documentation.

PBYI (Puma Biotechnology Inc) Net earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Analytical breakdowns for Puma Bio (PBYI)

- stock price and consensus target price:
Stock Price Puma Biotechnology Inc|PBYI - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Puma Biotechnology, Inc.|PBYI - Business Value
- shareholders' equity book value data:
Book Value per Share Puma Biotechnology|PBYI - Company Net Assets|Market Capitalization to Book Value Ratio pumabiotechnology.com|PBYI - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Puma Biotechnology|PBYI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Puma Biotechnology Inc|PBYI - Company Aggregate Indebtedness|Debt to Book Value Puma Biotechnology, Inc.|PBYI - Company Long-Term Debts|Company Short-Term Debt Puma Biotechnology|Quick Ratio pumabiotechnology.com
- net income and valuation multiples indicators:
PBYI - Net Profit|Future Profit Puma Biotechnology|PBYI - Company Value to Net Income|Forward P/E Multiple Puma Biotechnology Inc|PBYI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Puma Biotechnology, Inc.|PBYI - Operating income before deduction of amortization|Earnings per share for the last twelve months Puma Biotechnology|PBYI - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pumabiotechnology.com|PBYI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Puma Biotechnology
Summary company analysis:pumabiotechnology.com - PBYI
Mass-produced product of Puma Biotechnology Inc

This indicator measures annual net income allocated per share, allowing for an objective assessment of the business's real profitability regardless of the total volume of issuance. By analyzing the rolling earnings per share metric, an investor can track the commercialization efficiency of Nerlynx and the ability of Puma Biotechnology (PBYI) management to transform the oncology pipeline into a sustainable financial result for the portfolio.

Competitors of Puma Biotechnology (PBYI)

Olema Pharmaceuticals - Net earnings per share (EPS TTM)|GLSI - Net earnings per share (EPS TTM)|Zentalis (ZNTL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months MGNX|PSTV (Plus Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Processa Pharma (PCSA)|Net earnings per share (EPS TTM) EGRX